EDX Medical Group (LSE:EDX) announced on 30 October 2026 that Professor Michael Owen has become non-executive chairman with immediate effect, succeeding Jason Holt. The appointment of a figure from the pharmaceutical and biotech world comes weeks after the company signed an employee health screening contract with Arnold Clark Group. For readers of the FTSE AIM All Share Index, EDX is an early-stage diagnostics Business with a small Revenue base and a growing list of corporate customers.

What the company does

EDX Medical is a Cambridge-based digital diagnostics company. It develops and supplies tests and services aimed at earlier disease detection, hereditary risk assessment and the selection of treatments. It operates its own laboratory and offers an employee health screening programme to employers, using proprietary biomarker testing panels.

The new chairman

Professor Owen has experience across life sciences, R&D, and finance. He co-founded Kymab Limited and held senior positions at GlaxoSmithKline, and he sits on several biotech boards and advises Investment partnerships. He holds no ordinary shares in EDX. The announcement said his expertise is expected to help LSE:EDX as it develops its diagnostics portfolio.

The Arnold Clark contract

On 17 September 2026 LSE:EDX announced a three-year employee health contract with Arnold Clark Group. EDX will provide its health and wellbeing screening programme to about 11,600 employees across roughly 200 UK locations. The service uses proprietary biomarker panels covering more than 220 disease conditions, with a focus on early detection of cancer, cardiovascular disease and metabolic disorders, along with general health checks. EDX expects annual revenue from the agreement of about 1.4 million to 1.6 million pounds, and says it is in talks with other large UK employers.

Financial position

The Annual Report for the year ended 31 March 2026, published on 3 September, shows how small the business currently is. Revenue was 330,541 pounds, up from 122,608 pounds the year before, and the company deferred 860,000 pounds of invoiced revenue into the current year because order processing ran past the year end. The loss widened to about 5.76 million pounds from 3.59 million pounds. Cash at the year end was about 2.92 million pounds, up from 2.40 million pounds, helped by 5.5 million pounds raised from new share issues during the year.

Set against that, the expected Arnold Clark revenue is several times last year's total, which explains why the contract has drawn attention.

Corporate activity

EDX held its AGM on 28 September, hosted an investor presentation through Investor Meet Company in early October, and announced a private investor evening with Yellowstone Advisory on 3 November. Director dealings were reported on 4 September and 5 November, and the annual report and AGM notice were posted on 3 September.

Sector and index context

Employer-funded health screening and biomarker testing is a growing but competitive field, and AIM has several small diagnostics companies chasing the same corporate customers. Contract wins can transform a small company's revenue quickly, but they must be followed by delivery at scale.

Key risks

LSE:EDX remains loss-making and has used share issues to fund operations, so further fundraising is a possibility. Revenue is concentrated on a handful of customers, and the timing of recognised revenue can slip, as the deferral last year showed. Diagnostic claims depend on clinical evidence and acceptance by employers and employees.

What to watch next

Investors will watch the rollout of the Arnold Clark programme, any further employer contracts, the first interim figures under the new chairman and any change in the cash position. Updates on how many employees take up screening will indicate whether the revenue range given in September is achievable.